<DOC>
	<DOC>NCT00418249</DOC>
	<brief_summary>The primary objective of this study is to assess the safety and efficacy of topical AS101 as treatment for Female Androgenetic Alopecia (FAGA) in menopause women.</brief_summary>
	<brief_title>Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Ammonium trichloro(dioxoethylene-O,O'-)tellurate</mesh_term>
	<criteria>Women in menopause, over 50 years of age. Clinically diagnosed for AGA, according to Ludwig scale III. Women treated with chronic medications. Use of Minoxidil within 3 months prior to entering study. Women who have underwent hair transplantation. Use of drugs with androgenic or antiandrogenic effects. Any other type of hair loss.</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Androgenetic Alopecia</keyword>
	<keyword>Telogen effluvium</keyword>
	<keyword>Chronic telogen effluvium</keyword>
	<keyword>Menopause</keyword>
	<keyword>Female Androgenetic Alopecia (FAGA)</keyword>
</DOC>